Fast Track Group FTRK 深 滬
已收盤 08-07 16:00:00 美东时间
0.302
-0.014
-4.43%
華盛通- 最 高0.3125
- 今 開0.2917
- 成交量 6.09万股
- 最 低 0.2811
- 昨 收 0.316
- 總市值 6587.375
- 52周最高 1.04
- 市盈率 靜 --
- 換手率 279.24%
- 52周最低 0.2664
- 委 比 6.25%
- 總股本 2.18万
- 歷史最高 9.69
- 量 比 0.28
- 振 幅 9.94%
- 歷史最低 0.2664
- 每 手 1
- 風險率 0.14%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Context Therapeutics Reports Second Quarter 2026 Operating and Pipeline Progress
Context Therapeutics Inc. reported its Q2 2026 financial results, with cash reserves of $43 million expected to fund operations into Q4 2027. The company prioritized its CTIM-76 and CT-202 clinical programs, with initial data expected in Q2 2027. CTIM-76 showed encouraging interim results in platinum-resistant ovarian cancer patients, while CT-202 is set to begin its first patient dosing in Q3 2026. CT-95 development was discontinued. R&D expense...
08-05 20:14
Rein Therapeutics Announces Publication of Landmark LTI-03 Clinical Data in Nature Communications
Rein Therapeutics announced the publication of clinical data on LTI-03 in Nature Communications, showing significant reductions in lung scarring and inflammation markers in IPF patients. The first-in-human study demonstrated that LTI-03 was well-tolerated and safe, with no systemic absorption. The data support the ongoing Phase 2 RENEW trial, which aims to evaluate LTI-03's efficacy in improving lung function. This marks a promising step in treat...
08-04 12:00
Zai Lab receives Orphan Drug status for ADC for neuroendocrine carcinomas
The US FDA has granted Orphan Drug status to Zai Lab's (LAB) antibody-drug conjugate zocilurtatug pelitecan for neuroendocrine carcinomas. The asset previously received Fast Track designation for othe...
08-03 21:28
Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Candel Therapeutics granted stock options to three new employees, totaling 30,800 shares with an exercise price of $10.01 per share, under its 2025 Inducement Plan. The options vest 25% after one year and the remaining 75% in 36 monthly installments, contingent on continued employment. The company focuses on developing multimodal immunotherapies for cancer, with key products CAN-2409 and CAN-3110 in clinical trials, receiving FDA designations inc...
08-03 20:05
Radiopharm Theranostics Reports Business Update
Radiopharm Theranostics reported positive Phase 2b results for imaging agent RAD 101, with 93% of evaluable patients achieving the primary endpoint. The company plans to initiate a Phase 3 registrational trial for RAD 101 in Q4 2026. Additionally, the company raised approximately $12.5 million through an institutional offer and launched a $6 million Share Purchase Plan. RAD 204 showed promising early clinical signs in a Phase 1 trial, with the fi...
07-31 11:00
INmune Bio Receives R&D Rebates of Approximately $4.6 Million
INmune Bio Inc. received a $4.2 million R&D cash rebate from Australia and an additional $0.4 million from the UK, totaling $4.6 million. These rebates strengthen the company's financial position, extend its cash runway, and support the advancement of CORDStrom™ toward regulatory filings. CEO David Moss highlighted the significance of these non-dilutive funds in preserving momentum for near-term milestones. The rebates were generated through gove...
07-31 11:00
FAST TRACK GROUP's Fast Track Entertainment Subsidiary Collaborates To Establish Offline Regional Launchpad Initiative
FAST TRACK GROUP (NASDAQ:FTRK) ("Fast Track" or the "Company"), a leading entertainment-focused event management and celebrity agency company, announced that its subsidiary Fast Track Entertainment ("FTE"), alongside the regional division of one of the world’s largest major music label groups (the "...
07-27 20:33
Humacyte Announces FDA Acceptance of IND for First-In-Human Clinical Study of CTEV for Coronary Artery Bypass Grafting
Humacyte's CTEV, a bioengineered human blood vessel, has received FDA clearance for a Phase 2a clinical trial in coronary artery bypass grafting (CABG). The trial aims to evaluate the safety and efficacy of CTEV as an off-the-shelf alternative to traditional grafts, addressing the limitations of saphenous vein grafts. Preclinical studies in animals showed promising results, with CTEV demonstrating sustained patency and remodeling. Humacyte plans ...
07-27 12:00
9 Communication Services Stocks Moving In Tuesday's Pre-Market Session
Gainers TNL Mediagene (NASDAQ:TNMG) stock moved upwards by 19.5% to $0.39 during Tuesday's pre-market session. Token Cat (NASDAQ:TC) stock moved upwards by 10.32% to $1.71. The company's market cap stands at $40.9 million. Antelope Enterprise Hldgs (NASDAQ:AEHL) stock moved upwards by 7.46% to $0.72...
07-21 20:05
Oncolytics Biotech gains FDA Fast Track for pelareorep
The latest update is out from Oncolytics Biotech ( ($ONCY) ). On July 20, 2026,...
07-20 21:28
